Skip to main content
Top
Published in: BMC Medicine 1/2018

Open Access 01-12-2018 | Research article

Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis

Authors: Horace C. W. Choi, Mark Jit, Gabriel M. Leung, Kwok-Leung Tsui, Joseph T. Wu

Published in: BMC Medicine | Issue 1/2018

Login to get access

Abstract

Background

Although routine vaccination of females before sexual debut against human papillomavirus (HPV) has been found to be cost-effective around the world, its cost-benefit has rarely been examined. We evaluate both the cost-effectiveness and cost-benefit of routine female adolescent nonavalent HPV vaccination in Hong Kong to guide its policy, and by extension that of mainland China, on HPV vaccination. One major obstacle is the lack of data on assortativity of sexual mixing. Such difficulty could be overcome by inferring sexual mixing parameters from HPV epidemiologic data.

Methods

We use an age-structured transmission model coupled with stochastic individual-based simulations to estimate the health and economic impact of routine nonavalent HPV vaccination for girls at age 12 on cervical cancer burden and consider vaccine uptake at 25%, 50%, and 75% with at least 20 years of vaccine protection. Bayesian inference was employed to parameterize the model using local data on HPV prevalence and cervical cancer incidence. We use the human capital approach in the cost-benefit analysis (CBA) and GDP per capita as the indicative willingness-to-pay threshold in the cost-effectiveness analysis (CEA). Finally, we estimate the threshold vaccine cost (TVC), which is the maximum cost for fully vaccinating one girl at which routine female adolescent nonavalent HPV vaccination is cost-beneficial or cost-effective.

Results

As vaccine uptake increased, TVC decreased (i.e., economically more stringent) in the CBA but increased in the CEA. When vaccine uptake was 75% and the vaccine provided only 20 years of protection, the TVC was US$444 ($373–506) and $689 ($646–734) in the CBA and CEA, respectively, increasing by approximately 2–4% if vaccine protection was assumed lifelong. TVC is likely to be far higher when non-cervical diseases are included. The inferred sexual mixing parameters suggest that sexual mixing in Hong Kong is highly assortative by both age and sexual activity level.

Conclusions

Routine HPV vaccination of 12-year-old females is highly likely to be cost-beneficial and cost-effective in Hong Kong. Inference of sexual mixing parameters from epidemiologic data of prevalent sexually transmitted diseases (i.e., HPV, chlamydia, etc.) is a potentially fruitful but largely untapped methodology for understanding sexual behaviors in the population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pink J, Parker B, Petrou S. Cost effectiveness of HPV vaccination: a systematic review of modelling approaches. Pharmacoeconomics. 2016;34(9):847–61.CrossRefPubMed Pink J, Parker B, Petrou S. Cost effectiveness of HPV vaccination: a systematic review of modelling approaches. Pharmacoeconomics. 2016;34(9):847–61.CrossRefPubMed
2.
3.
go back to reference Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Mak. 2006;26(5):434–46.CrossRef Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Mak. 2006;26(5):434–46.CrossRef
4.
go back to reference Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.CrossRefPubMed Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.CrossRefPubMed
5.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
6.
go back to reference Drolet M, Benard E, Boily M-C, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JML, Cummings T, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80.CrossRefPubMedPubMedCentral Drolet M, Benard E, Boily M-C, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JML, Cummings T, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80.CrossRefPubMedPubMedCentral
7.
go back to reference Korostil IA, Peters GW, Cornebise J, Regan DG. Adaptive Markov chain Monte Carlo forward simulation for statistical analysis in epidemic modelling of human papillomavirus. Stat Med. 2013;32(11):1917–53.CrossRefPubMed Korostil IA, Peters GW, Cornebise J, Regan DG. Adaptive Markov chain Monte Carlo forward simulation for statistical analysis in epidemic modelling of human papillomavirus. Stat Med. 2013;32(11):1917–53.CrossRefPubMed
8.
go back to reference Korostil IA, Peters GW, Law MG, Regan DG. Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. Vaccine. 2013;31(15):1931–6.CrossRefPubMed Korostil IA, Peters GW, Law MG, Regan DG. Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. Vaccine. 2013;31(15):1931–6.CrossRefPubMed
9.
go back to reference Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016;213(9):1444–54.CrossRefPubMed Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016;213(9):1444–54.CrossRefPubMed
10.
go back to reference Boiron L, Joura E, Largeron N, Prager B, Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016;16:153.CrossRefPubMedPubMedCentral Boiron L, Joura E, Largeron N, Prager B, Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016;16:153.CrossRefPubMedPubMedCentral
11.
go back to reference Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;259(8):821–32.CrossRef Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;259(8):821–32.CrossRef
12.
go back to reference The Hong Kong College of Obstetricians and Gynaecologists. Guidelines on the Management of Abnormal Cervical Cytology. Hong Kong: The Hong Kong College of Obstetricians and Gynaecologists; 2008. The Hong Kong College of Obstetricians and Gynaecologists. Guidelines on the Management of Abnormal Cervical Cytology. Hong Kong: The Hong Kong College of Obstetricians and Gynaecologists; 2008.
13.
go back to reference Van de Velde N, Brisson M, Boily M-C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165(7):762–75.CrossRefPubMed Van de Velde N, Brisson M, Boily M-C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165(7):762–75.CrossRefPubMed
15.
go back to reference Walker R, Nickson C, Lew J-B, Smith M, Canfell K. A revision of sexual mixing matrices in models of sexually transmitted infection. Stat Med. 2012;31(27):3419–32.CrossRefPubMed Walker R, Nickson C, Lew J-B, Smith M, Canfell K. A revision of sexual mixing matrices in models of sexually transmitted infection. Stat Med. 2012;31(27):3419–32.CrossRefPubMed
16.
go back to reference Mercer CH, Copas AJ, Sonnenberg P, Johnson AM, McManus S, Erens B, Cassell JA. Who has sex with whom? Characteristics of heterosexual partnerships reported in a national probability survey and implications for STI risk. Int J Epidemiol. 2009;38(1):206–14.CrossRefPubMed Mercer CH, Copas AJ, Sonnenberg P, Johnson AM, McManus S, Erens B, Cassell JA. Who has sex with whom? Characteristics of heterosexual partnerships reported in a national probability survey and implications for STI risk. Int J Epidemiol. 2009;38(1):206–14.CrossRefPubMed
17.
go back to reference Badcock PB, Smith AMA, Richters J, Rissel C, de Visser RO, Simpson JM, Grulich AE. Characteristics of heterosexual regular relationships among a representative sample of adults: the second Australian study of health and relationships. Sex Health. 2014;11(5):427–38.CrossRefPubMed Badcock PB, Smith AMA, Richters J, Rissel C, de Visser RO, Simpson JM, Grulich AE. Characteristics of heterosexual regular relationships among a representative sample of adults: the second Australian study of health and relationships. Sex Health. 2014;11(5):427–38.CrossRefPubMed
18.
go back to reference Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data. 2005;(362):1–55. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. Adv Data. 2005;(362):1–55.
20.
go back to reference Chan PKS, Ho WCS, Wong MCS, Chang AR, Chor JSY, Yu M-Y. Epidemiologic risk profile of infection with different groups of human papillomaviruses. J Med Virol. 2009;81:1635–44.CrossRefPubMed Chan PKS, Ho WCS, Wong MCS, Chang AR, Chor JSY, Yu M-Y. Epidemiologic risk profile of infection with different groups of human papillomaviruses. J Med Virol. 2009;81:1635–44.CrossRefPubMed
21.
go back to reference Liu SS, Chan KYK, Leung RCY, Chan KKL, Tam KF, Luk MHM, Lo SST, Fong DYT, Cheung ANY, Lin ZQ, et al. Prevalence and risk factors of human papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One. 2011;6(5):e19244.CrossRefPubMedPubMedCentral Liu SS, Chan KYK, Leung RCY, Chan KKL, Tam KF, Luk MHM, Lo SST, Fong DYT, Cheung ANY, Lin ZQ, et al. Prevalence and risk factors of human papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One. 2011;6(5):e19244.CrossRefPubMedPubMedCentral
23.
go back to reference Chan PKS, Ho WCS, Yu M-Y, Pong W-M, Chan ACL, Chan AKC, Cheung T-H, Wong MCS, To K-F, Ng H-K. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer. 2009;125(7):1671–7.CrossRefPubMed Chan PKS, Ho WCS, Yu M-Y, Pong W-M, Chan ACL, Chan AKC, Cheung T-H, Wong MCS, To K-F, Ng H-K. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer. 2009;125(7):1671–7.CrossRefPubMed
24.
go back to reference Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarker Prev. 2011;20(2):287–96.CrossRef Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarker Prev. 2011;20(2):287–96.CrossRef
25.
go back to reference Moscicki A-B, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116:1373–80.CrossRefPubMedPubMedCentral Moscicki A-B, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116:1373–80.CrossRefPubMedPubMedCentral
28.
go back to reference Choi HCW, Leung GM, Woo PPS, Jit M, Wu JT. Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents. Vaccine. 2013;32(1):78–84.CrossRefPubMed Choi HCW, Leung GM, Woo PPS, Jit M, Wu JT. Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents. Vaccine. 2013;32(1):78–84.CrossRefPubMed
31.
go back to reference Malagon T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–9.CrossRefPubMed Malagon T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–9.CrossRefPubMed
32.
go back to reference Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, Chatterjee A, Iversen O-E, Joshi A, Chu J-L, et al. 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140(6):e20163947.CrossRefPubMed Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, Chatterjee A, Iversen O-E, Joshi A, Chu J-L, et al. 4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140(6):e20163947.CrossRefPubMed
33.
go back to reference Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324–33.CrossRefPubMed Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324–33.CrossRefPubMed
34.
go back to reference Leung GM, Woo PPS, Cowling BJ, Tsang CSH, Cheung ANY, Ngan HYS, Galbraith K, Lam T-H. Who receives, benefits from and is harmed by cervical and breast cancer screening among Hong Kong Chinese? J Public Health. 2008;30(3):282–92.CrossRef Leung GM, Woo PPS, Cowling BJ, Tsang CSH, Cheung ANY, Ngan HYS, Galbraith K, Lam T-H. Who receives, benefits from and is harmed by cervical and breast cancer screening among Hong Kong Chinese? J Public Health. 2008;30(3):282–92.CrossRef
35.
go back to reference Wu JT. Cervical cancer prevention through cytologic and human papillomavirus DNA screening in Hong Kong Chinese women. Hong Kong Med J. 2011;17(Suppl 3):S20–4. Wu JT. Cervical cancer prevention through cytologic and human papillomavirus DNA screening in Hong Kong Chinese women. Hong Kong Med J. 2011;17(Suppl 3):S20–4.
36.
go back to reference Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287(18):2382–90.CrossRefPubMed Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287(18):2382–90.CrossRefPubMed
37.
go back to reference Hutton G, Rehfuess E. Guidelines for Conducting Cost-Benefit Analysis of Household Energy and Health Interventions. Geneva: WHO Press; 2006. Hutton G, Rehfuess E. Guidelines for Conducting Cost-Benefit Analysis of Household Energy and Health Interventions. Geneva: WHO Press; 2006.
38.
go back to reference Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: a systematic review. Vaccine. 2017;35(24):3153–61.CrossRefPubMed Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: a systematic review. Vaccine. 2017;35(24):3153–61.CrossRefPubMed
41.
go back to reference Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Mak. 2007;27(4):414–22.CrossRef Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Mak. 2007;27(4):414–22.CrossRef
42.
go back to reference Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778–92.CrossRefPubMed Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778–92.CrossRefPubMed
43.
go back to reference World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. In: Tan-Torres Edejer T, Baltussen RMPM, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL, editors. . Geneva: WHO; 2003. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. In: Tan-Torres Edejer T, Baltussen RMPM, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL, editors. . Geneva: WHO; 2003.
44.
go back to reference Prah P, Copas AJ, Mercer CH, Nardone A, Johnson AM. Patterns of sexual mixing with respect to social, health and sexual characteristics among heterosexual couples in England: analyses of probability sample survey data. Epidemiol Infect. 2015;173(7):1500–10.CrossRef Prah P, Copas AJ, Mercer CH, Nardone A, Johnson AM. Patterns of sexual mixing with respect to social, health and sexual characteristics among heterosexual couples in England: analyses of probability sample survey data. Epidemiol Infect. 2015;173(7):1500–10.CrossRef
45.
go back to reference Brisson M, Benard E, Drolet M, Bogaards JA, Baussano I, Vanska S, Jit M, Boily MC, Smith MA, Berkhof J, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8–e17.CrossRefPubMed Brisson M, Benard E, Drolet M, Bogaards JA, Baussano I, Vanska S, Jit M, Boily MC, Smith MA, Berkhof J, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8–e17.CrossRefPubMed
46.
go back to reference Herlihy N, Hutubessy R, Jit M. Current global pricing for HPV vacc brings the greatest econ benefits to rich countries. Health Aff. 2015;35(2):227–34.CrossRef Herlihy N, Hutubessy R, Jit M. Current global pricing for HPV vacc brings the greatest econ benefits to rich countries. Health Aff. 2015;35(2):227–34.CrossRef
47.
go back to reference Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Br Med J. 2011;343:d5775.CrossRef Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. Br Med J. 2011;343:d5775.CrossRef
48.
go back to reference Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018;36(19):2529–44.CrossRefPubMed Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018;36(19):2529–44.CrossRefPubMed
49.
go back to reference Simms KT, Laprise J-F, Smith MA, Lew J-B, Caruana M, Brisson M, Canfell K. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health. 2016;1(2):e66–75.CrossRefPubMed Simms KT, Laprise J-F, Smith MA, Lew J-B, Caruana M, Brisson M, Canfell K. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health. 2016;1(2):e66–75.CrossRefPubMed
50.
go back to reference Brisson M, Laprise J-F, Chesson HW, Drolet M, Malagon T, Boily M-C, Markowitz LE. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 2016;108(1):djv282.CrossRefPubMed Brisson M, Laprise J-F, Chesson HW, Drolet M, Malagon T, Boily M-C, Markowitz LE. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 2016;108(1):djv282.CrossRefPubMed
51.
go back to reference Chesson HW, Laprise J-F, Brisson M, Markowitz LE. Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine. J Infect Dis. 2016;213(11):1694–700.CrossRefPubMedPubMedCentral Chesson HW, Laprise J-F, Brisson M, Markowitz LE. Impact and cost-effectiveness of 3 doses of 9-valent human papillomavirus (HPV) vaccine among US females previously vaccinated with 4-valent HPV vaccine. J Infect Dis. 2016;213(11):1694–700.CrossRefPubMedPubMedCentral
52.
go back to reference Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model. Hum Vaccin Immunother. 2016;12(6):1363–72.CrossRefPubMedPubMedCentral Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model. Hum Vaccin Immunother. 2016;12(6):1363–72.CrossRefPubMedPubMedCentral
53.
go back to reference Drolet M, Laprise J-F, Boily M-C, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264–8.CrossRefPubMed Drolet M, Laprise J-F, Boily M-C, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264–8.CrossRefPubMed
54.
go back to reference Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2016;17(1):85–98.CrossRefPubMed Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2016;17(1):85–98.CrossRefPubMed
55.
go back to reference Kiatpongsan S, Kim JJ. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two east African countries. PLoS One. 2014;9(9):e106836.CrossRefPubMedPubMedCentral Kiatpongsan S, Kim JJ. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two east African countries. PLoS One. 2014;9(9):e106836.CrossRefPubMedPubMedCentral
56.
go back to reference Mo X, Tobe RG, Wang L, Liu X, Wu B, Luo H, Nagata C, Mori R, Nakayama T. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017;17:502.CrossRefPubMedPubMedCentral Mo X, Tobe RG, Wang L, Liu X, Wu B, Luo H, Nagata C, Mori R, Nakayama T. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017;17:502.CrossRefPubMedPubMedCentral
57.
go back to reference Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK? Vaccine. 2014;32(16):1828–33.CrossRefPubMedPubMedCentral Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK? Vaccine. 2014;32(16):1828–33.CrossRefPubMedPubMedCentral
58.
go back to reference Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.CrossRefPubMed Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–89.CrossRefPubMed
59.
go back to reference Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. Valuing vaccines using value of statistical life measures. Vaccine. 2014;32(39):5065–70.CrossRefPubMed Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. Valuing vaccines using value of statistical life measures. Vaccine. 2014;32(39):5065–70.CrossRefPubMed
60.
go back to reference Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, Macdowall W, Lewis R, Field N, Datta J, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of sexual attitudes and lifestyles (Natsal). Lancet. 2013;382(9907):1781–94.CrossRefPubMedPubMedCentral Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, Macdowall W, Lewis R, Field N, Datta J, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of sexual attitudes and lifestyles (Natsal). Lancet. 2013;382(9907):1781–94.CrossRefPubMedPubMedCentral
61.
go back to reference Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci U S A. 2016;113(18):5107–12.CrossRefPubMedPubMedCentral Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci U S A. 2016;113(18):5107–12.CrossRefPubMedPubMedCentral
Metadata
Title
Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis
Authors
Horace C. W. Choi
Mark Jit
Gabriel M. Leung
Kwok-Leung Tsui
Joseph T. Wu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2018
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-018-1118-3

Other articles of this Issue 1/2018

BMC Medicine 1/2018 Go to the issue